CCA
NXTC icon

Catalyst Capital Advisors’s NextCure NXTC Stock Holding History

Catalyst Capital Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37
Closed -$14K – 384
2019
Q3 		$14K Hold
37
– – ﹤0.01% 321
2019
Q2 		$7K Buy
+37
New +$7.69K ﹤0.01% 350

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalyst Capital Advisors's NXTC Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of NextCure (NXTC) in Q4 2019, closing a stake of 37 shares — an estimated $14K sold.

Catalyst Capital Advisors first reported a position in NXTC in Q2 2019 and held it in 2 quarters. The position peaked at $14K in Q3 2019. 88 funds tracked by Wall St. Rank hold NXTC as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining NextCure position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 37 NextCure shares in Q4 2019, an estimated $14K.
  • Catalyst Capital Advisors first reported a position in NextCure in Q2 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's NextCure position peaked at $14K in Q3 2019.
  • 88 funds tracked by Wall St. Rank held NextCure as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.